C3C


Also found in: Wikipedia.
AcronymDefinition
C3CCadet 3rd Class
C3CCivilization III: Conquest Expansion (computer game)
C3CCommunications Control Center for Centrex Management
References in periodicals archive ?
Patients were grouped according to normal (75-140 mg/dL) versus elevated (>140 mg/dL) C3c levels; 33 (16.8%) of all evaluated heart failure patients had elevated C3c levels.
No differences regarding age were found in patients with normal versus elevated C3c values (P = 0.77).
We found a trend towards smaller end-diastolic (59 [+ or -] 11 mm versus 63 [+ or -] 10 mm; P = 0.059) and end-systolic (44 [+ or -] 13 mm versus 47 [+ or -] 13 mm; P = 0.099) diameters of the left ventricle and towards a higher left ventricular ejection fraction (48.0 [+ or -] 12.83% versus 43.5 [+ or -] 13.2%; P = 0.092) in patients with elevated complement C3c (Figure 1).
Lower values of NTpro-BNP were found in patients with elevated C3c (468 [246; 1182] pg/mL versus 1117 [385; 2662] pg/mL; P = 0.018; Figure 2).
CRP levels were significantly higher in patients with elevated C3c (0.91 [+ or -] 0.18 mg/dL versus 0.55 [+ or -] 0.08 mg/dL; P < 0.001).
We found relevant alterations in the blood profile of patients with elevated C3c: higher values for platelets (252 [+ or -] 108 versus 202 [+ or -] 53 x 1000/[micro]L; P = 0.001), erythrocytes (4.73[+ or -] 0.46 versus 4.50 [+ or -] 0.58 x 10E6/[micro]L; P = 0.040), and leukocytes (8.45 [+ or -] 2.76 versus 7.45 [+ or -] 3.92 x 1000/[micro]L; P = 0.016) but no differences regarding haemoglobin (13.94 [+ or -] 0.14 versus 14.14 [+ or -] 0.25 g/dL; P = 0.70).
Twenty-two patients (13.5%) in the group with normal C3c compared to only 1 (3.0%) patient in the group with elevated C3c died during the follow-up.
However, here we present data that elevated complement C3c levels in patients with heart failure are associated with a trend towards improved survival and better cardiac reverse remodeling (i.e., reduced left ventricular volume, increased ejection fraction, and reduced NT-proBNP values).
Second, we used C3c, a stable conversion product which develops out of C3 within one hour at body temperature [15].
However, activation of an immune response in our cohort could be demonstrated by an association of C3c and increased leucocytes and C-reactive protein levels.
We present data that elevated C3c levels seem to be associated with less adverse remodeling and improved survival in patients with stable systolic heart failure.